Allogeneic hematopoietic cell transplantation (HCT) is the only therapy for MDS with curative potential. Of the estimated 15,000 to 20,000 US patients diagnosed annually, >80% are >age 70 years. Care of patients with MDS requires understanding the disease in the context of an older population, and tailoring approaches to both disease risk and patient suitability for therapy.
In this free continuing education webinar a physician and nurse practitioner will present current research and case examples to illustrate treatment options and common experiences for older patients with MDS and their families. The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with MDS. Attendees are encouraged to submit questions for a Q&A
CE/CME approved for:
Hematology, oncology nurses; hematology, oncology social workers at intermediate to advanced levels of practice, experience and licensure; and clinical laboratory professionals.
- Outline treatment considerations for older patients with myelodysplastic syndromes (MDS) based on comorbidities, disease risk level and patient risk stratification.
- Discuss evidence-based definitions of fitness to inform treatment decisions.
- Identify supportive care considerations for older adults undergoing treatment for MDS.
- Describe strategies for psychosocial support and education for older patients and their families.
Marlise R. Luskin, MD, MSCE
Physician in Dana-Farber’s Adult Leukemia program
Ilene Galinsky, NP
Senior Program Research Nurse Practitioner for the Adult Leukemia Program with the Dana Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital /BWH in Boston, Massachusetts